CERC vs. AVDL, SUPN, EWTX, TARO, ZLAB, HRMY, SDGR, CPRX, KURA, and DAWN
Should you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Edgewise Therapeutics (EWTX), Taro Pharmaceutical Industries (TARO), Zai Lab (ZLAB), Harmony Biosciences (HRMY), Schrödinger (SDGR), Catalyst Pharmaceuticals (CPRX), Kura Oncology (KURA), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "medical" sector.
Cerecor (NASDAQ:CERC) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
Avadel Pharmaceuticals has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Avadel Pharmaceuticals' return on equity of -198.06% beat Cerecor's return on equity.
Avadel Pharmaceuticals has a consensus price target of $23.67, suggesting a potential upside of 25.75%. Given Avadel Pharmaceuticals' higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Cerecor.
Cerecor has higher earnings, but lower revenue than Avadel Pharmaceuticals. Cerecor is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
62.8% of Cerecor shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 45.7% of Cerecor shares are held by insiders. Comparatively, 4.0% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Avadel Pharmaceuticals received 142 more outperform votes than Cerecor when rated by MarketBeat users. However, 74.00% of users gave Cerecor an outperform vote while only 65.01% of users gave Avadel Pharmaceuticals an outperform vote.
Cerecor has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
In the previous week, Avadel Pharmaceuticals had 5 more articles in the media than Cerecor. MarketBeat recorded 5 mentions for Avadel Pharmaceuticals and 0 mentions for Cerecor. Avadel Pharmaceuticals' average media sentiment score of 0.49 beat Cerecor's score of 0.16 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
Summary
Avadel Pharmaceuticals beats Cerecor on 12 of the 17 factors compared between the two stocks.
Get Cerecor News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
